GSKGlaxoSmithKlineSigning up patients
A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL
Lymphoma, Non-Hodgkin
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 49 (planned)
- Started
- Jun 19, 2026
- Main results expected
- Jan 10, 2030
- Fully finished
- Jan 10, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with dose limiting toxicities (DLTs)
Measured over: Up to 28 days
Number of participants with adverse events (AEs) or Serious adverse events (SAEs) by severity
Measured over: Up to approximately 169 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07607925 · record last updated 2026-10-30 · checked 2026-11-09 15:47 UTC